secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2024-02-02T23:59:59+00:00
Accession:  0001804220-24-000006
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron Q4 revenues $3.43B (+1% YoY); Dupixent up 31%; full-year guidance issued
--------------------------------------------------------------------------------

- Q4 GAAP EPS $10.19, non-GAAP $11.86; FY GAAP EPS $34.77, non-GAAP $43.79.
- Dupixent global net sales Q4 $3.22B (+31% YoY), FY $11.59B (+33%). EYLEA franchise U.S. net sales down 2% in Q4.
- Pipeline: Dupixent COPD sBLA and linvoseltamab BLA submitted; EYLEA HD approved in EU/Japan.
- FY2024 guidance: GAAP R&D $4.82-5.07B, SG&A $2.89-3.09B, gross margin 86-88%.
- Share repurchases $2.215B in FY2023; $1.5B remain. CFO Robert Landry to retire.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000180422024000006/0001804220-24-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000180422024000006/regn-20240202.htm
  HTML page:      https://secwatch.observer/filing/0001804220-24-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer